These data not only provide insights into a mechanism of Dox-induced platelet activation, thrombosis, and drug-induced thrombocytopenia, but also reveal putative precision therapeutic approaches for Dox-treated patients and nominate CLEC-2 inhibition as a means to regulate thrombotic disease and/or bleeding disorders. The gene discussed is CLEC1B; the disease is Thrombocytopenia.